Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
| Brand name | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE |
| Generic name | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE |
| Active ingredient(s) | HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM |
| Distributed by / for | Macleods Pharma USA inc. Plainsboro, NJ 08536 |
| NDC | 33342-050-10 |
| Full product label | Losartan Potassium and Hydrochlorothiazide Tablets, USP 50 mg/12.5 mg 90 Tablets, USP Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536 Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA NDC 33342-050-10 |
| Recalling firm | Macleods Pharma Usa Inc |
| Distribution | Nationwide |
| Quantity | 142626 bottles (12,836,340 tablets) |
| Recall initiated | 2019-06-20 |
| Report date | 2019-07-17 |
| Recall completed | 2021-10-26 |
| Recall number | D-1459-2019 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Plainsboro NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗